Faron Pharmaceuticals Oy Manager's transactions (5828R)
October 27 2023 - 7:00AM
UK Regulatory
TIDMFARN
RNS Number : 5828R
Faron Pharmaceuticals Oy
27 October 2023
Faron Pharmaceuticals Ltd.
("Faron" or the "Company")
Managers' transactions
Company announcement, October 27, 2023 at 3:00 pm (EEST)
Inside Information
TURKU, Finland / BOSTON, Massachusetts - October 27 , 2023 -
Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company pioneering macrophage
reprogramming for effective anticancer immunotherapies , announces
today that John Poulos, a Non-executive Director of the Company, on
October 3, 2023 sold 5,000 ordinary shares in Faron at a price of
EUR3.7209 per share, and on October 12, 2023, sold 5,000 ordinary
shares in Faron at a price of EUR3.8259 per share. Following these
disposals, John Poulos directly holds 10,000 ordinary shares in the
Company, representing 0.02 per cent. of the Company's issued share
capital.
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
---- -------------------------------------------------------------------------------------
a. Name John Poulos
---------------------------------------------------------
2 Reason for notification
-------------------------- ---------------------------------------------------------
a. Position/Status Non-executive Director
-------------------------- ---------------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
-------------------------- ---------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------------
a. Name Faron Pharmaceuticals Oy
--------------------------
b. LEI 7437009H31TO1DC0EB42
-------------------------- ---------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---- -------------------------------------------------------------------------------------
a. Description of Ordinary shares
the financial
instrument, type ISIN: FI4000153309
of instrument
Identification
Code
-------------------------- ---------------------------------------------------------
b. Nature of the 1) Disposal of ordinary shares (October
transaction 3, 2023)
2) Disposal of ordinary shares (October
12, 2023)
-------------------------- ---------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
-------------------------- -------------------
1) EUR3.7209 1) 5,000
2) EUR3.8259 2) 5,000
------------------- -----------------
d. Aggregated information
- Aggregated Volume 1) 5,000
2) 5,000
- Price 1) EUR3.7209
2) EUR3.8259
-----------------------------------------------------------------------------------------
e. Date of the transaction 1) October 3, 2023
2) October 12, 2023
-----------------------------------------------------------------------------------------
f. Place of the transaction Nasdaq First North Growth Market
-------------------------- ---------------------------------------------------------
For more information please contact:
Investor Contact
LifeSci Advisors
Daniel Ferry
Managing Director
daniel@lifesciadvisors.com
+1 (617) 430-7576
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global,
clinical-stage biopharmaceutical company, focused on tackling
cancers via novel immunotherapies. Its mission is to bring the
promise of immunotherapy to a broader population by uncovering
novel ways to control and harness the power of the immune system.
The Company's lead asset is bexmarilimab, a novel anti-Clever-1
humanized antibody, with the potential to remove immunosuppression
of cancers through targeting myeloid cell function. Bexmarilimab is
being investigated in Phase I/II clinical trials as a potential
therapy for patients with hematological cancers in combination with
other standard treatments. Further information is available at
www.faron.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPGPWUUPWGGM
(END) Dow Jones Newswires
October 27, 2023 08:00 ET (12:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024
